Supplier
BIOTOSCANA URUGUAY S.A.
R/211231950010
Total received
- Contracts
- 2.356
- Agencies that bought from them
- 22
- Average contract
- $ 110.707
- Years with activity
- 19
- First contract
- 27 mar. 2007
- Last contract
- 24 jun. 2025
BIOTOSCANA URUGUAY S.A. received $ 261 M from the Uruguayan state across 2.356 awards between 2007 and 2025. It sold to 22 agencies. Its largest buyer is Dirección General de la Salud, with 11% of recorded spending.
What it bid for, and against whom
Open data publishes only the winner, so losing bids appear nowhere. This comes from the bidders each purchase record publishes. It covers the 9 calls of this company we have checked so far, not all of them: the scan advances gradually.
Who it meets most often
- MEGALABS URUGUAY S A4 times
- GRAMON BAGO DE URUGUAY S A3 times
- LABORATORIO GADOR S A3 times
- URUFARMA S.A.3 times
- LABORATORIO LIBRA SOCIEDAD ANONIMA3 times
- APITER S.A.2 times
- FARMACO URUGUAYO S.A.2 times
- GLAXOSMITHKLINE URUGUAY S A .2 times
State Suppliers Registry (RUPE)
ACTIVO- Legal name
- BIOTOSCANA URUGUAY S.A.
- Fiscal domicile
- Montevideo SALDANHA DA GAMA 3622 Apto. 311, - View on Google Maps
Source: ARCE — Registro Único de Proveedores del Estado (RUPE), open data. Cross-referenced to the supplier by RUT.
Revenue by year
Who buys from them
Agencies ranked by amount awarded to this supplier.
- Dirección General de la Salud$ 203 M
- Banco de Previsión Social$ 49,5 M
- Dirección Nacional de Sanidad de las Fuerzas Armadas$ 12,7 M
- Hospital Pasteur$ 8,1 M
Client concentration
11%
Dirección General de la Salud
How much of their revenue comes from their largest buyer.
Contracts
View all| Subject | Agency | Date | Amount |
|---|---|---|---|
| CARFILZOMIB ( INYECTABLE) | Dirección General de la Salud | 24 jun. 2025 | $ 400.000 |
| MORFINA (INYECTABLE) · CEFOVECINA ( USO VETERINARIO)… | Facultad de Veterinaria | 15 ene. 2025 | $ 191.764 |
| CABAZITAXEL (INYECTABLE) | Dirección General de la Salud | 29 oct. 2024 | $ 27.000 |
| CARFILZOMIB ( INYECTABLE) | Dirección General de la Salud | 29 oct. 2024 | $ 312.000 |
| POMALIDOMIDA · CARFILZOMIB ( INYECTABLE) | Dirección General de la Salud | 28 oct. 2024 | $ 198.000 |
| POMALIDOMIDA · CARFILZOMIB ( INYECTABLE) | Dirección General de la Salud | 28 oct. 2024 | $ 198.000 |
| CABAZITAXEL (INYECTABLE) | Dirección General de la Salud | 28 oct. 2024 | $ 27.000 |
| CARFILZOMIB ( INYECTABLE) | Dirección General de la Salud | 28 oct. 2024 | $ 156.000 |
2.356 suppliers